Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

NEXT STORY
LifeWatch’s Largest Shareholders Accept BioTelemetry, Inc.’s Tender Offer for LifeWatch AG
PREV STORY
OpGen to Receive Ignaz Semmelweis Award for Commitment to Combatting Infection Deaths
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock

author_avatar
NASDAQ Market News

electroCore, Inc. to Report Second Quarter Financial Results on August 13, 2018

BASKING RIDGE, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a ...

author_avatar
NASDAQ Market News

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer

author_avatar
NASDAQ Market News